GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shield Therapeutics PLC (LSE:STX) » Definitions » Float Percentage Of Total Shares Outstanding

Shield Therapeutics (LSE:STX) Float Percentage Of Total Shares Outstanding : 0.00% (As of May. 26, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Shield Therapeutics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Shield Therapeutics's float shares is 0.00 Mil. Shield Therapeutics's total shares outstanding is 782.06 Mil. Shield Therapeutics's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Shield Therapeutics's Insider Ownership is 4.05%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Shield Therapeutics's Institutional Ownership is 7.90%.

Shield Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Shield Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=0.00/782.06
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shield Therapeutics (LSE:STX) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shield Therapeutics PLC (LSE:STX) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
LSE:CEL LSE:VLG LSE:AGY LSE:EAH LSE:CHLL LSE:PXS LSE:HELD AQSE:ANA LSE:N4P LSE:ANCR ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
SHIEF:USA 1JS:Germany
Address
Northern Design Centre, Baltic Business Quarter, Gateshead Quays, Newcastle, GBR, NE8 3DF
Website
https://www.shieldtherapeutics.com
Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals which address areas of high unmet medical need. The company's operating segments are based on key products including Accrufer/Feraccru, used as a novel oral treatment for iron deficiency anemia in patients, which is commercially available, and PT20 used in treating hyperphosphatemia, which is in its last stage of completion. The company generates maximum revenue from Feraccru segment.